MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) announced that data from a multicenter, prospective, randomized, blinded, feasibility trial published today show promise for occipital nerve stimulation (ONS) for treating medically refractory chronic migraines and support the need for further controlled study of the treatment. The study, called Occipital Nerve Stimulation for the Treatment of Intractable Migraine (ONSTIM), included severely debilitated patients who had regularly experienced 15 or more headache days per month that were not responsive to currently available medical therapies. Findings were published in the international headache journal, Cephalalgia, and represent the first publication of randomized, controlled data examining ONS for the treatment of chronic migraine. These preliminary data will form the basis for a pivotal clinical trial to demonstrate safety and effectiveness and support market authorization.
